Clinical Impact of Serum <scp>CRP</scp> Levels on Advanced <scp>HCC</scp> Treated With Durvalumab and Tremelimumab: A Multicentre Study

Takeshi Hatanaka; Yutaka Yata; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Satoru Kakizaki; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hidenori Toyoda; Yuichi Koshiyama; Chikara Ogawa; Hiroki Nishikawa; Takashi Nishimura; Kazuhito Kawata; Hisashi Kosaka; Kosuke Matsui; Atsushi Naganuma; Hironori Tanaka; Hideko Ohama; Hidekatsu Kuroda; Tomomitsu Matono; Tomoko Aoki; Hironori Ochi; Michitaka Imai; Shinichiro Nakamura; Yuki Kanayama; Kazunari Tanaka; Fujimasa Tada; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Hirayuki Enomoto; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada

doi:10.1111/liv.70192

Article2025

Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

Article2025

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake,

Article2025

Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Satoru Kakizaki, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka,

Article2024

Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.

Ciro Celsa, Naoshi Nishida, Ashwini Arvind, Susanna V. Ulahannan, Michael Li, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Giulia Francesca Manfredi, Bernardo Stefanini, Giuseppe Cabibbo, Alessio Cortellini, Matthias Pinter, Robin Kate Kelley, Paul Antoine El Tomb, Amit G. Singal, Masatoshi Kudo, David J. Pinato

Article2024

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Sara Cabrero‐de las Heras, Xavier Hernández‐Yagüe, Andrea González, Ferrán Losa, Gemma Soler, Cristina Bugés, Iosune Baraibar, Anna Esteve, Miguel Ángel Pardo-Cea, Anne Hansen Ree, Neus Martínez-Bosch, Maria Nieva, Eva Musulen, Sebastian Meltzer, Tania Lobato, Carla Vendrell-Ayats, Cristina Queralt, Pilar Navarro, Clara Montagut, Ferran Grau‐Leal, David Camacho, Raquel Legido,

Clinical Impact of Serum <scp>CRP</scp> Levels on Advanced <scp>HCC</scp> Treated With Durvalumab and Tremelimumab: A Multicentre Study

Abstract

Discussion(0)

Related publications

Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment